Associates
Michael Kilbourn
Dr. Michael R. Kilbourn (B.S. Biochemistry, Ph.D. Organic Chemistry) has three decades of experience in all facets of PET radiopharmaceutical research and production, from cyclotron target design and evaluation, to development of innovative methods for radiochemical synthesis using short-lived radionuclides such as carbon-11 and fluorine-18, through design and synthesis of novel new PET radiopharmaceuticals, and finally to pre-clinical evaluation and validation (including animal imaging) and eventual first-in-man clinical trials. His contributions to new methods for radiochemical syntheses and new radiopharmaceuticals for oncology, neurology and cardiology are now routinely utilized for PET research worldwide. Dr. Kilbourn has extensive practical experience in the management and operation of a PET radiochemistry program (including quality control and quality assurance procedures) delivering multiple different radiopharmaceuticals daily for both pre-clinical and clinical imaging. He also brings practical experience in the design and construction a new Cyclotron and Radiochemistry Facility, including selection of the cyclotron, hot cells, and automated radiochemistry equipment for a combined clinical service and research program routinely delivering radiopharmaceuticals labeled with carbon-11, fluorine-18, nitrogen-13 and oxygen-15.